Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

VAS2870

Catalog No: tcsc0012525

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
722456-31-7

Formula:
$C_{18}H_{12}N_6OS$

Pathway:
Others

Target:
Others

Purity / Grade:
>98%

Solubility:
DMSO : 83.3 mg/mL (231.14 mM; Need ultrasonic)

Observed Molecular Weight:
360.39

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

VAS2870 is a **NADPH oxidase (NOX)** inhibitor.

IC50 & Target: Target: NADPH oxidase[1]

In Vitro: VAS2870 is effective to suppress PDGF-BB-dependent activation of NADPH oxidase and subsequent production of intracellular ROS. Furthermore, VAS2870 suppresses PDGF-BB-dependent chemotaxis, but not DNA synthesis. Preincubation with VAS2870 (10 and 20 μM) completely abolishes PDGF-mediated NADPH oxidase activation and ROS production. Preincubation with VAS2870 (0.1-20 μM) does not affect PDGF-induced cell cycle progression. However, it abolishes PDGF-dependent chemotaxis of VSMC in a concentration-dependent manner (100% inhibition at 10 μM)[1]. VAS2870 inhibits dose-dependently autocrine increase of cell number in FaO rat hepatoma cells, and almost completely blocked ROS production and thymidine incorporation when used at 25 mM. VAS2870 blocks serum-dependent cell growth of FaO rat hepatoma cells. VAS2870 inhibits proliferation of different human hepatocellular carcinoma (HCC) cell lines. VAS2870 pretreatment enhances TGF-b-mediated apoptosis of FaO rat hepatoma cells[2].